Vitek Michael P, Brown Candice M, Colton Carol A
Duke University Medical Center, Durham, NC 27710, USA.
Neurobiol Aging. 2009 Sep;30(9):1350-60. doi: 10.1016/j.neurobiolaging.2007.11.014. Epub 2007 Dec 21.
Apolipoprotein-E protein is an endogenous immunomodulatory agent that affects both the innate and the adaptive immune responses. Since individuals with the APOE4 gene demonstrate worsened pathology and poorer outcomes in many neurological disorders, we examined isoform-specific differences in the response of microglia, the primary cellular component of the brain's innate immune response, in detail. Our data demonstrate that microglia derived from APOE4/4 targeted replacement mice demonstrate a pro-inflammatory phenotype that includes altered cell morphology, increased NO production associated with increased NOS2 mRNA levels, and higher pro-inflammatory cytokine production (TNFalpha, IL-6, IL12p40) compared to microglia derived from APOE3/3 targeted replacement mice. The effect is gene dose-dependent and increases with the number of APOE4 gene alleles. The APOE genotype-specific immune profile observed in the microglial immune response is also observed in the cortex of aged APOE3/3 and APOE4/4 mice treated with lipopolysacchride (LPS) and in peripheral (peritoneal) macrophages. To determine if APOE4's action resulted from an isoform-specific difference in effective levels of the apolipoproteins, we generated mice expressing only a single allele of APOE3. Immune-stimulated macrophages from APOE3/0 mice demonstrated an increased inflammatory response compared to APOE3/3 mice, but less than in APOE4/4 mice. These data suggest that inhibition of inflammation depends upon the dose of apoE3 protein available and that apoE4 protein may alter inflammation partly by dose effects and partly by being qualitatively different than apoE3. Overall, these data emphasize the important role of apolipoprotein E and of the APOE genotype on the immune responses that are evident in most, if not all, neurological disease.
载脂蛋白E蛋白是一种内源性免疫调节剂,可影响先天性和适应性免疫反应。由于携带APOE4基因的个体在许多神经疾病中表现出更严重的病理状况和更差的预后,我们详细研究了小胶质细胞(大脑先天性免疫反应的主要细胞成分)反应中的异构体特异性差异。我们的数据表明,与源自APOE3/3靶向替代小鼠的小胶质细胞相比,源自APOE4/4靶向替代小鼠的小胶质细胞表现出促炎表型,包括细胞形态改变、与NOS2 mRNA水平升高相关的一氧化氮产生增加以及更高的促炎细胞因子产生(TNFα、IL-6、IL12p40)。这种效应具有基因剂量依赖性,并随着APOE4基因等位基因数量的增加而增强。在小胶质细胞免疫反应中观察到的APOE基因型特异性免疫特征,在接受脂多糖(LPS)治疗的老年APOE3/3和APOE4/4小鼠的皮质以及外周(腹膜)巨噬细胞中也有观察到。为了确定APOE4的作用是否源于载脂蛋白有效水平的异构体特异性差异,我们培育了只表达单个APOE3等位基因的小鼠。与APOE3/3小鼠相比,来自APOE3/0小鼠的免疫刺激巨噬细胞表现出更强的炎症反应,但比APOE4/4小鼠弱。这些数据表明,炎症的抑制取决于可用的载脂蛋白E3蛋白的剂量,并且载脂蛋白E4蛋白可能部分通过剂量效应,部分通过与载脂蛋白E3在性质上不同来改变炎症。总体而言,这些数据强调了载脂蛋白E和APOE基因型在大多数(如果不是全部)神经疾病中明显的免疫反应中的重要作用。